Role of Dapagliflozin in MASH
Primary Recommendation
Dapagliflozin cannot be recommended as a MASH-targeted therapy, but it is safe to use and should be prescribed for its approved indications—type 2 diabetes, heart failure, and chronic kidney disease—in patients who also have MASLD/MASH. 1
Guideline-Based Position on SGLT2 Inhibitors for MASH
Current Evidence Status
The 2024 EASL-EASD-EASO guidelines explicitly state there is insufficient evidence to recommend SGLT2 inhibitors (including dapagliflozin) as MASH-targeted therapies, as controlled clinical trials with liver histological endpoints are not available. 1
Despite the lack of MASH-specific approval, SGLT2 inhibitors are safe to use in MASLD and should be prescribed for their respective indications: type 2 diabetes, heart failure, and chronic kidney disease (LoE 3, strong recommendation, strong consensus). 1
Resmetirom is currently the only medication with robust Phase III histological efficacy data for MASH-targeted therapy in patients with F2-F3 fibrosis, if locally approved. 1
Preferred Treatment Algorithm by Disease Stage
For non-cirrhotic MASLD/MASH (F0-F3) with comorbid type 2 diabetes: Use GLP-1 receptor agonists (e.g., semaglutide, liraglutide, dulaglutide) or co-agonists (e.g., tirzepatide) as preferred agents, with SGLT2 inhibitors (empagliflozin, dapagliflozin) as additional options for cardiometabolic benefit. 1
For MASLD/MASH with compensated cirrhosis (F4) and type 2 diabetes: Insulin is preferred in decompensated cirrhosis; metformin can be used if eGFR >30 mL/min/1.73 m². 1
SGLT2 inhibitors can be used in Child-Pugh class A and B cirrhosis (LoE 4, weak recommendation, consensus). 1
Emerging Research Evidence (Not Yet Guideline-Endorsed)
Recent Randomized Controlled Trial Data
A 2025 Chinese multicenter RCT (n=154) demonstrated that dapagliflozin 10 mg daily for 48 weeks resulted in MASH improvement without worsening fibrosis in 53% of participants versus 30% with placebo (RR 1.73,95% CI 1.16-2.58, P=0.006). 2
MASH resolution without worsening fibrosis occurred in 23% with dapagliflozin versus 8% with placebo (RR 2.91,95% CI 1.22-6.97, P=0.01). 2
Fibrosis improvement without worsening MASH was reported in 45% with dapagliflozin versus 20% with placebo (RR 2.25,95% CI 1.35-3.75, P=0.001). 2
The mean difference in NAS (non-alcoholic fatty liver disease activity score) was -1.39 (95% CI -1.99 to -0.79, P<0.001). 2
Limitations of Current Research
This single Phase III trial, while promising, has not yet been incorporated into international guidelines, and long-term liver-related outcomes (decompensation, hepatocellular carcinoma, liver-related mortality) remain unknown. 2
A 2025 Japanese RCT (n=24) showed dapagliflozin reduced liver enzymes and body fat but was associated with a significant decline in skeletal muscle index, raising concerns about sarcopenia risk and potential adverse effects on long-term survival. 3
Practical Off-Label Use Considerations
When Dapagliflozin May Be Considered
For patients with MASH and comorbid type 2 diabetes, obesity, cardiovascular disease, or CKD (eGFR ≥25 mL/min/1.73 m²), dapagliflozin should be prescribed primarily for its cardiovascular and renal protective benefits, with potential secondary hepatic benefit. 4, 5
The standard dose is dapagliflozin 10 mg once daily, with no dose adjustment required for cardiovascular or renal protection when eGFR ≥25 mL/min/1.73 m². 4, 5
Dosing and Monitoring
Initiate dapagliflozin 10 mg once daily if eGFR ≥25 mL/min/1.73 m² for cardiovascular/renal protection; for glycemic control alone, initiation requires eGFR ≥45 mL/min/1.73 m². 4, 5
Check eGFR within 1-2 weeks after initiation; an expected reversible dip of 2-5 mL/min/1.73 m² should not prompt discontinuation. 5
Monitor for genital mycotic infections (≈6% incidence) and educate patients about euglycemic diabetic ketoacidosis risk. 5
Withhold dapagliflozin during acute illness with reduced oral intake, fever, vomiting, or diarrhea, and stop at least 3 days before major surgery. 5
Given the sarcopenia signal in one small trial, monitor skeletal muscle mass (e.g., via InBody or DEXA) in patients at risk for muscle loss. 3
Medication Adjustments
If combining with insulin or sulfonylureas, reduce their doses by ~20% to mitigate hypoglycemia risk. 5
Consider reducing concurrent loop or thiazide diuretic doses to prevent excessive volume depletion, especially in elderly patients. 5
Continue ACE inhibitors or ARBs unchanged when starting dapagliflozin. 5
Common Pitfalls to Avoid
Do not discontinue dapagliflozin solely because eGFR falls below 45 mL/min/1.73 m²; cardiovascular and renal benefits persist despite reduced glycemic efficacy. 4, 5
Do not stop dapagliflozin in response to the expected early eGFR dip; this change is hemodynamic and reversible. 5
Do not reduce the dapagliflozin dose below 10 mg for cardiovascular or renal indications; all outcome trials used the fixed 10 mg dose. 5
Do not prescribe dapagliflozin as a MASH-targeted therapy in the absence of comorbid diabetes, heart failure, or CKD, as this is not guideline-supported. 1
Comparison with Other Agents
GLP-1 receptor agonists are preferred over SGLT2 inhibitors for patients with MASLD/MASH and type 2 diabetes, as they provide superior weight loss and potential histological benefit, though they also lack formal MASH-targeted approval. 1
Pioglitazone is safe in non-cirrhotic MASH but cannot be recommended as MASH-targeted therapy due to lack of robust Phase III histological efficacy data. 1
Vitamin E cannot be recommended as MASH-targeted therapy due to lack of robust Phase III efficacy and potential long-term risks. 1
Metformin should not be discontinued in patients with cirrhosis (unless contraindicated by hepatic decompensation or renal failure), as observational data suggest it may improve transplant-free survival. 1
Summary Algorithm
- Confirm MASH diagnosis (ideally by biopsy or validated non-invasive markers). 1
- Assess for comorbid type 2 diabetes, heart failure, or CKD. 1, 4
- If comorbidities present and eGFR ≥25 mL/min/1.73 m²: Initiate dapagliflozin 10 mg daily for cardiovascular/renal protection, with potential secondary hepatic benefit. 4, 5, 2
- If no comorbidities: Prioritize lifestyle modification, weight loss, and consider resmetirom (if F2-F3 fibrosis and locally approved) or GLP-1 receptor agonists for obesity. 1
- Monitor skeletal muscle mass in patients at risk for sarcopenia. 3
- Re-assess eGFR, liver enzymes, and metabolic parameters at 3-6 months. 5